Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1624 1654 1675
This examiner grants 33% of resolved cases
Randall L. Beane serves in Art Unit 1612 of Tech Center 1600. He has managed 454 resolved cases with an allowance rate of 32.8%. This percentage shows the frequency of grants for applications assigned to his docket. Practitioners should note that the 32.8% allowance rate reflects the examination process for the 454 resolved cases. This metric suggests that many applications face hurdles during prosecution in this unit.
The interview lift is 36.8%. This figure is notable because it exceeds the base allowance rate of 32.8%, which suggests that interviews are an effective tool for this examiner. Engaging in a formal interview correlates with an increase in the probability of a grant. The 36.8% lift is a key metric for developing a prosecution strategy. For those navigating this docket, the lift represents a path to improving outcomes through direct communication.
The median days to allowance is 1199. This duration indicates the typical time from filing to grant. The 1199-day timeline provides a specific expectation for pendency. By combining the allowance rate and the 1199-day figure, practitioners can better navigate the prosecution of applications within Tech Center 1600. These data points offer a comprehensive view of the examiner's historical performance and procedural tendencies.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18290734 | CONTROLLING PRO-INFLAMMATORY MACROPHAGE PHENOTYPE THROUGH BIOFUNCTIONAL HYDROGEL DESIGN | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17276711 | BIOLOGICAL BITS AS COMPUTABLE ELEMENTS WITHIN LIVING SYSTEMS | Non-Final OA | GEORGIA TECH RESEARCH CORPORATION |
| 18467797 | Compositions and Methods of Treatment Using CRRL 191 | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18551959 | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17598761 | MIXTURES OF SYNTHETIC COPOLYPEPTIDE HYDROGELS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18334253 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A VAGINAL INFECTION OF GARDNERELLA VAGINALIS | Non-Final OA | Massachusetts Institute of Technology |
| 18041815 | INSULIN RECEPTOR PARTIAL AGONISTS | Final Rejection | Merck Sharp & Dohme LLC |
| 18037549 | CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18268399 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 16628162 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | Final Rejection | CHILDREN'S MEDICAL CENTER CORPORATION |
| 18695068 | PEPTIDE HAVING ACTIVITY OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 18038607 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | Non-Final OA | CAREGEN CO., LTD. |
| 18683180 | IL-2/IL-15RBETAGAMMA AGONIST COMBINATION WITH ANTIBODY-DRUG CONJUGATES FOR TREATING CANCER | Non-Final OA | Cytune Pharma |
| 18248101 | CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE | Non-Final OA | SERVIZO GALEGO DE SAÚDE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy